Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Binding Hot Spots in the TEM1–BLIP Interface in Light of its Modular Architecture

Autor: Reichmann, D., Cohen, M., Abramovich, R., Dym, O., Lim, D., Strynadka, N.C.J., Schreiber, G.

Publikováno v: In Journal of Molecular Biology 19 January 2007 365(3):663-679

Population differences in antibody response to SARS-CoV-2 infection and BNT162b2 vaccination.

Autor: Shapira G; Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel., Abu Hamad R; Shamir Medical Center, Be'er Yaacov, Israel., Weiner C; Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Shamir Medical Center, Be'er Yaacov, Israel., Rainy N; Shamir Medical Center, Be'er Yaacov, Israel., Sorek-Abramovich R; Shamir Medical Center, Be'er Yaacov, Israel., Benveniste-Levkovitz P; Shamir Medical Center, Be'er Yaacov, Israel., Rock R; Shamir Medical Center, Be'er Yaacov, Israel., Avnat E; Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Levtzion-Korach O; Shamir Medical Center, Be'er Yaacov, Israel., Bar Chaim A; Shamir Medical Center, Be'er Yaacov, Israel., Shomron N; Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel.

Publikováno v: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2022 Apr; Vol. 36 (4), pp. e22223.

Particle Forming Amorphous Solid Dispersions: A Mechanistic Randomized Pharmacokinetic Study in Humans.

Autor: Schittny A; Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, 4056 Basel, Switzerland., Waldner S; Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland., Duthaler U; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, 4056 Basel, Switzerland., Vorobyev A; Department of Pharmtechnology, Faculty of Advanced Training of Medical Workers, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Abramovich R; Department of Pharmtechnology, Faculty of Advanced Training of Medical Workers, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia., Krähenbühl S; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, 4056 Basel, Switzerland.; Department of Clinical Research, University of Basel, 4056 Basel, Switzerland., Puchkov M; Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland., Huwyler J; Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.; Department of Clinical Research, University of Basel, 4056 Basel, Switzerland.

Publikováno v: Pharmaceutics [Pharmaceutics] 2021 Mar 17; Vol. 13 (3). Date of Electronic Publication: 2021 Mar 17.

SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.

Autor: Hajaj E; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel.; Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University, Jerusalem, Israel., Eisenberg G; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel., Klein S; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel., Frankenburg S; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel., Merims S; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel., Ben David I; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel., Eisenhaure T; Broad Institute of MIT and Harvard, Cambridge, United States., Henrickson SE; Broad Institute of MIT and Harvard, Cambridge, United States.; Boston Children's Hospital, Department of Pediatrics, Boston, United States., Villani AC; Broad Institute of MIT and Harvard, Cambridge, United States.; Center for Cancer Research, Massachusetts General Hospital, Charlestown, United States.; Department of Medicine, Harvard Medical School, Boston, United States.; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, United States., Hacohen N; Broad Institute of MIT and Harvard, Cambridge, United States.; Center for Cancer Research, Massachusetts General Hospital, Charlestown, United States.; Department of Medicine, Harvard Medical School, Boston, United States., Abudi N; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel.; Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel., Abramovich R; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel.; Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel., Cohen JE; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel., Peretz T; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel., Veillette A; IRCM, Montreal Clinical Research Institute, Montreal, Canada., Lotem M; Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.; Wohl Institute for Translational Medicine, Hadassah Medical Organization, Jerusalem, Israel.; Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Publikováno v: ELife [Elife] 2020 Mar 03; Vol. 9. Date of Electronic Publication: 2020 Mar 03.